Resumen de Duodenal carbidopa/levodopa: An opportunity for advanced Parkinson's disease patients
Mónica Gayoso Rey, Luis Manuel López Díaz
Objective: To describe the efficacy and safety of Levodopa-Carbidopa Intestinal Gel treatment (LCIG) in a patient with advanced Parkinson's Disease (PD) at a first level hospital. Method: Clinical data, disease progress and previous treatments to LCIG administration were gathered from the patient's electronic medical record. The Unified Parkinson's Disease Rating Scale (UPDRS) and the Schwab & England Activities of Daily Living Scale (ADL) were used for measuring the patient's response to LCIG. Results: After ambulatory oral levodopa/carbidopa, rasagiline and rotigotine treatment, the patient was hospitalized due to motor and non-motor fluctuations (anxiety, insomnia, dysphagia). During her stay, entacapone and apomorphine were added to the treatment with no response. Therefore, LCIG was administered. Conclusion: LCIG treatment caused an improvement in motor and non-motor fluctuations. Tube obstruction problems may cause treatment interruption
